DAPAGLIFLOZIN ACCEPTED FOR USE WITHIN NHS SCOTLAND

Breaking News Today – 12th April 2021

AstraZeneca today announced that Forxiga (dapagliflozin) has been accepted for use within NHS Scotland by the Scottish Medicines Consortium (SMC) as an additional option for the treatment of symptomatic chronic heart failure (HF) with reduced ejection fraction (rEF) in adults, as an add-on to already optimised standard care.

Read the two press releases

Scottish Medicines Press Release

AstraZeneca Press Release